Inhibrx Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	186.57	152.6	277.92	-
Cash & Short-Term Investments	186.57	152.6	277.92	-
Cash Growth	-17.76%	-45.09%	-	-
Accounts Receivable	0.24	0.4	0.78	0.24
Other Receivables	0.73	0.02	-	0.01
Receivables	0.97	0.42	0.78	0.26
Inventory	2.48	2	9.89	0.81
Prepaid Expenses	2.45	4.19	5.67	4.53
Other Current Assets	1.5	1.2	1.09	0.67
Total Current Assets	193.96	160.4	295.36	6.26
Property, Plant & Equipment	11.35	13.54	9.37	7.22
Other Long-Term Assets	6.81	6.83	3.16	3.16
Total Assets	212.12	180.77	307.89	16.65
Accounts Payable	16.73	14.89	33.76	9.45
Accrued Expenses	20.04	24.25	20.49	9.46
Current Portion of Leases	2.17	1.6	2.06	1.86
Total Current Liabilities	38.94	40.73	56.31	20.77
Long-Term Debt	99.28	-	206.97	-
Long-Term Leases	5.34	6.45	1.11	3.17
Total Liabilities	143.56	47.18	264.39	23.95
Common Stock	0	0	0.01	-7.3
Additional Paid-In Capital	246.66	239.72	657.23	-
Retained Earnings	-178.1	-106.13	-613.73	-
Shareholders' Equity	68.56	133.58	43.5	-7.3
Total Liabilities & Equity	212.12	180.77	307.89	16.65
Total Debt	106.79	8.05	210.14	5.03
Net Cash (Debt)	79.78	144.55	67.78	-5.03
Net Cash Growth	-64.49%	113.25%	-	-
Net Cash Per Share	5.16	9.65	5.75	-
Filing Date Shares Outstanding	14.49	14.48	11.78	-
Total Common Shares Outstanding	14.48	14.48	11.78	-
Working Capital	155.03	119.67	239.05	-14.51
Book Value Per Share	4.74	9.23	3.69	-
Tangible Book Value	68.56	133.58	43.5	-7.3
Tangible Book Value Per Share	4.74	9.23	3.69	-
Machinery	10.31	10.31	9.02	7.55
Construction In Progress	0.02	-	3.59	-
Leasehold Improvements	0.8	0.8	0.44	0.44

Updated Aug 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q